Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - PhaseBio Pharmaceuticals Inc | a10-q2020q1.htm |
| EX-32.1 - EXHIBIT 32.1 - PhaseBio Pharmaceuticals Inc | ex-321xphas10xq2020q1.htm |
| EX-31.2 - EXHIBIT 31.2 - PhaseBio Pharmaceuticals Inc | ex312-phas10xq2020q1.htm |
| EX-31.1 - EXHIBIT 31.1 - PhaseBio Pharmaceuticals Inc | ex311-phas10xq2020q1.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of PhaseBio Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(1) | The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; as amended; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: May 12, 2020 | By: | /s/ John Sharp | |
John Sharp Chief Financial Officer | |||